TrialBlood advances2024

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).

Tycel J Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.